Form 4: Axsome CCO Maizel Exercises, Sells 7,500 Shares

Axsome Therapeutics' Chief Commercial Officer, Ari Maizel, exercised stock options and subsequently sold 7,500 shares of common stock for a significant gain.

Summary

• Ari Maizel, Chief Commercial Officer of Axsome Therapeutics, Inc. (AXSM), engaged in a pre-approved transaction under a Rule 10b5-1 plan.
• On January 21, 2026, Mr. Maizel exercised stock options to acquire 7,500 shares of Common Stock at an exercise price of $70.73 per share.
• Immediately following the exercise on the same date, Mr. Maizel sold all 7,500 of these newly acquired shares of Common Stock.
• The shares were sold at a weighted average price of $184.44 per share, with individual sale prices ranging between $183.70 and $184.81.
• After these transactions, Mr. Maizel beneficially owns 0 shares of Common Stock from this specific transaction, but retains 31,210 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The transaction represents a pre-planned exercise of stock options and subsequent sale of shares by an insider, which is a routine event and does not inherently indicate a positive or negative outlook for the company.

Positives

• The Chief Commercial Officer realized a significant profit from the exercise of stock options and subsequent sale of shares, demonstrating the value of his equity compensation.

Negatives

• The sale of shares by an insider, even under a pre-approved 10b5-1 plan, can sometimes be viewed with caution by investors, though the pre-planned nature mitigates concerns about opportunistic selling.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may note the Chief Commercial Officer's exercise of stock options and subsequent sale of shares, a routine transaction under a pre-approved 10b5-1 plan. This type of transaction is generally not considered a strong signal of future company performance.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, insider trading, stock option exercise, share sale, Ari Maizel, Chief Commercial Officer, 10b5-1 plan